brinzolamide ophthalmic suspension 1% / Generic mfg. - LARVOL DELTA

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Enhanced in vivo performance of topical ocular acetazolamide nanocrystals: A novel approach for glaucoma treatment. (PubMed, Int J Pharm) - "High intraocular pressure (IOP) is the main risk factor for glaucoma progression. Further, in vivo studies revealed a significant IOP reduction of up to 32 % of the basal IOP (-4.8 ± 1.2 mmHg, p < 0.05) in normotensive rabbit eyes (n = 7), after 4 h of AZM-NC suspension topical application, compared to groups treated with AZM suspension, normal saline solution and, AZOPT® (-1.8 ± 1.4 mmHg). Thus, AZM-NC could present a promising approach for developing an eye drop formulation for the localized management of glaucoma."

Journal • Preclinical • Glaucoma • Ophthalmology

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=500 | Completed | Sponsor: University of Miami | Active, not recruiting ➔ Completed | Trial completion date: Jul 2025 ➔ Oct 2024 | Trial primary completion date: Jul 2025 ➔ Oct 2024

Trial completion • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=500 | Active, not recruiting | Sponsor: University of Miami | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=500 | Active, not recruiting | Sponsor: University of Miami

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Topical Pharmacokinetics of Brinzolamide Suspensions in Rabbits and Variability Analysis for Sample Size and Design Considerations. (PubMed, Int J Pharm) - "In this study the marketed antiglaucoma product Azopt® (1% brinzolamide suspension) and five other brinzolamide formulations varying in particle size distributions and apparent viscosities were topically administered in rabbits, and their ocular pharmacokinetics was determined in multiple ocular tissues...For example, when the true difference in aqueous humor C is 25%, nine rabbits are required in the paired-eye design versus seventy rabbits (35 per treatment) in the parallel-group design to observe a statistically significant difference with a power of 80%. Therefore, the proposed paired-eye dosing design is a viable option for the design of pharmacokinetic studies comparing ophthalmic products to determine the impact of formulation differences."

Journal • PK/PD data • Preclinical • Glaucoma • Ophthalmology

Impact of Variations in Critical Quality Attributes of Brinzolamide Ophthalmic Suspensions on Preclinical Pharmacokinetics and Pharmacodynamics Following Once-Daily Topical Instillations (ARVO 2023) - "Test formulations (BRZ_001 – 005) and reference product Azopt were characterized for particle size distribution (PSD) and apparent viscosity...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

PK/PD data • Preclinical • Glaucoma • Ophthalmology

Enhanced Ocular Tissue Permeation of Brinzolamide Administered via OcuSurf LNP (ARVO 2023) - "We present enhancement of transport of LNP-BZ (compared to Azopt) through cornea and scleral tissues, via Franz Diffusion cells...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Glaucoma • Ophthalmology

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P3 | N=599 | Completed | Sponsor: Sun Pharmaceutical Industries Limited | Recruiting ➔ Completed | Trial completion date: Jun 2023 ➔ Jan 2023 | Trial primary completion date: May 2023 ➔ Dec 2022

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P3 | N=666 | Recruiting | Sponsor: Sun Pharmaceutical Industries Limited | Trial completion date: Nov 2022 ➔ Jun 2023 | Trial primary completion date: Oct 2022 ➔ May 2023

Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

AAV2/4-RS1 gene therapy in the retinoschisin knockout mouse model of X-linked retinoschisis. (PubMed, PLoS One) - "AAV2/4-RS1 shows promise for improving retinal phenotype in the Rs1-KO mouse model. Subretinal delivery was superior to intravitreal. Topical brinzolamide did not improve efficacy. AAV2/4-RS1 may be considered as a potential treatment for XLRS patients."

Journal • Preclinical • Cytomegalovirus Infection • Gene Therapies • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: University of the Incarnate Word | N=24 ➔ 0 | Trial completion date: Jan 2022 ➔ May 2022 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Jul 2021 ➔ May 2022

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Glaucoma • Ophthalmology

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P3 | N=666 | Recruiting | Sponsor: Sun Pharmaceutical Industries Limited | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2022 ➔ Nov 2022 | Trial primary completion date: Mar 2022 ➔ Oct 2022

Enrollment open • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Novel cubosome based system for ocular delivery of acetazolamide. (PubMed, Drug Deliv) - "F5 showed mean residence time 4.22 h vs. 2.36 and 2.62 h for Azopt and Cidamex with no eye irritation observed according to the modified Draize test. To the best of our knowledge, this is the first study for developing acetazolamide-loaded cubosomes as the topical delivery system for glaucoma treatment."

Journal • Glaucoma • Metabolic Disorders • Ophthalmology

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3; N=500; Active, not recruiting; Sponsor: University of Miami; Recruiting ➔ Active, not recruiting

Enrollment closed • Glaucoma • Ophthalmology

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P3; N=666; Not yet recruiting; Sponsor: Sun Pharmaceutical Industries Limited

Clinical • New P3 trial • Glaucoma • Ophthalmology

Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana. (PubMed, Clinicoecon Outcomes Res) - "Azopt (Brimonidine) was the most expensive with daily treatment cost of GHC 5.8 (about US$ 1.45), whilst the least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops. Prostaglandin analogs though expensive remain the most preferred treatment for managing glaucoma at the Korle-Bu Eye Centre in Ghana. This may adversely affect treatment among the poor since prostaglandins analogs are currently not covered by insurance."

Clinical • HEOR • Journal • Glaucoma • Ophthalmology

Ocular Microemulsion of Brinzolamide: Formulation, Physicochemical Characterization, and in vitro Irritation Studies based on EpiOcular™ Eye Irritation Assay. (PubMed, Pharm Dev Technol) - "Bioadhesion studies were performed using Texture analysis. Finally, in vitro ocular irritation based on EpiOcular™ Eye Irritation Test and cytocompatibility studies was performed to examine any possible harm on ocular cells and predict in vivo safety profile."

Journal • Preclinical • Glaucoma • Ophthalmology

Prophylactic effect of brinzolamide-brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections. (PubMed, Int Ophthalmol) - "The prophylactic administration of one drop of brinzolamide-brimonidine fixed combination significantly reduces the IOP spikes during the first 30 min after the intravitreal anti-VEGF injection."

Journal

[VIRTUAL] The effect of intraocular pressure-lowering drugs on non-pigmented ciliary epithelium-derived exosomes interactions and their impact on trabecular meshwork internalization (ARVO 2021) - "To evaluate the ionic strength (IS) effects on exosomes size and ZP, different PBS buffer strengths, eye drops solutions used for POAG treatment; Alphagan-P®, V-OPTIC®, AZOPT®, Lumigan®, and Travatan®, their active ingredients; Timolol maleate, Brinzolamide or their preservative benzalkonium chloride were analyzed. Our findings suggest that exosomes size, surface membrane charge, and IS of the surrounding, have an impact on exosomes:exosomes interactions which affect the uptake of NPCE exosomes by TM cells."

Glaucoma • Ophthalmology

[VIRTUAL] Insulin for retinal ganglion cell dendrite regeneration: effect of intraocular pressure and identification of multiple downstream pathways (ARVO 2021) - "Daily topical application of brinzolamide, a carbonic anhydrase inhibitor with negligible effects on neurons or vascular cells, was used to reduce IOP... We conclude that: 1) IOP reduction alone is not sufficient to promote RGC dendrite regeneration, and 2) multiple downstream pathways are activated during insulin-mediated regeneration. These findings support a critical role for exogenous insulin administration, and identify differential gene expression of potential targets to restore RGC function in glaucoma."

Glaucoma • Ophthalmology • mTOR • THY1

[VIRTUAL] Aqueous misdirection syndrome masking as myopic surprise: a case report and review of literature (ARVO 2021) - " Case report A 68-year-old Caucasian woman with previous narrow anterior chamber (AC) angle treated with bilateral peripheral iridotomies on Brinzolamide eye drops presented with symptoms of anisometropia and a left eye (LE) myopic surprise a few months after an uncomplicated LE phacoemulsification procedure... Clinical presentation of aqueous misdirection syndrome may be subtle and can occur weeks to years after routine uncomplicated phacoemulsification surgery. Short axial lengths, hypermetropia, female gender and shallow anterior chamber depths (ACD) are known risk factors. Myopic surprise may be the only initial presenting sign, and measurements of ACD, IOP and gonioscopic examination are essential when clinicians are suspecting aqueous misdirection syndrome on patients who has had recent uneventful cataract surgery."

Clinical • Review • Cataract • Glaucoma • Ophthalmology

Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome. (PubMed, Ophthalmic Genet) - "Background: Cohen Syndrome (CS) is an autosomal recessive multisystemic disorder characterized by various ophthalmologic findings, including retinal dystrophy and associated cystoid macular edema (CME), in which there was no known effective treatment approach.Material and We describe a CS patient with a homozygous c.62 T > G, p.(Leu21*) mutation in the VPS13B gene with a topical carbonic anhydrase inhibitor (CAI; brinzolamide %1, thrice daily) responding CME.Case Description: A seven-year-old girl with an established diagnosis of CS was referred with a primary complaint of nyctalopia...Visual acuity increased, and CME was resolved except for minimal schisis at the inner nuclear layer level at the third-month follow-up visit and remained stable up to one-year follow-up. CME reappeared after five months of self-discontinuation of the patient's therapy but resolved again with treatment resumption. We report the first case of CME secondary to rod-cone..."

Clinical • Journal • Inherited Retinal Dystrophy • Macular Edema • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa • CD5

Bilateral Acute Angle Closure Glaucoma after Prone Position Ventilation for COVID 19 Pneumonia. (PubMed, J Glaucoma) - "Following intravenous mannitol (20%) infusion, oral acetazolamide 250▒mg three times daily, along with topical therapy with combination Brimonidine and Brinzolamide eye drops and Fluoromethalone eye drops his corneal edema resolved and subsequent to laser iridotomy his intraocular pressures lowered significantly and could be maintained below 16▒mm Hg in both eyes with topical therapy alone. With prone position ventilation being a commonly employed adjuvant treatment for acute respiratory distress syndrome associated with COVID 19 pneumonia, acute angle closure may be precipitated in these patients if they have pre-existing narrow angles. Awareness of the possibility and its recognition may allow prompt ophthalmic referral, early treatment and minimise visual consequences."

Journal • Acute Respiratory Distress Syndrome • Glaucoma • Infectious Disease • Novel Coronavirus Disease • Ophthalmology • Pneumonia • Pulmonary Disease • Respiratory Diseases

Development and validation of a fast ultra high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for determining carbonic anhydrase inhibitors and their metabolites in urine and hair. (PubMed, Drug Test Anal) - "Average hair concentrations were 5.94 ng/mg for dorzolamide and 0.048 ng/mg for N-deethyl-dorzolamide (n=3); 3.26 ng/mg for brinzolamide (n=2) and 2.3 ng/mg for acetazolamide (n=1). The developed method was simple and fast both in the extraction procedure making it eligible in high-throughput analysis for clinical forensic and doping purposes."

Journal • Hypertension • Ophthalmology